Skip to main content
. 2023 Jul 10;14:1197275. doi: 10.3389/fimmu.2023.1197275

Figure 14.

Figure 14

(A)The expression level of ENO1, ACO1 and ACSL4 in primary FLS of rat model with knockdown of ENO1-siRNA (n=3). (B) The expression level of ENO1 and ACO1 in primary FLS of RA patients(n=3). (C, D) The expression level of ENO1, ACO1 and ACSL4 in primary FLS of rat model and RA patients with knockdown of ENO1-siRNA in the presence of ferrous iron (200 μmol/L), Lip-1 (1 μmol/), Fer-1 (1 μmol/) (n=3). (E) The assessment of cell viability by CCK-8 assay in primary FLS of rat models with knockdown of ENO1-SiRNA in the presence of ferrous iron (200 μmol/L), Lip-1 (1 μmol/), Fer-1 (1 μmol/). Data are means ± SD. *P < 0.05, ****P < 0.0001 and ns (no significance) versus RA group; ###P < 0.001 versus siRNA group. ****P < 0.0001 versus siRNA group; #P < 0.05 and ##P < 0.01 versus siRNA+Fe2+group. (F) The assessment of cell viability by CCK-8 assay in primary FLS of RA patients with knockdown of ENO1-SiRNA in the presence of ferrous iron (200 μmol/L), Lip-1 (1 μmol/), Fer-1 (1 μmol/). Data are means ± SD. *P < 0.05, ****P < 0.0001 and ns (no significance) versus RA group; ###P < 0.001 versus siRNA group. *P < 0.05 versus siRNA group; #P < 0.05 versus siRNA+Fe2+group.